Table 1 Baseline characteristics of the study population.

From: Effect of simultaneous presence of anti-blood group A/B and -HLA antibodies on clinical outcomes in kidney transplantation across positive crossmatch: a nationwide cohort study

 

aABOc/XM+

aABOi/XM+

P-value

Number of patients

176 (66.9)

87 (33.1)

 

Mean age (years)

48.7 ± 11.9

51.4 ± 9.6

0.12

Female sex

46 (26.1)

42 (48.3)

<0.01

Body mass index (kg/m2)

22.2 ± 3.1

25.5 ± 13.5

0.06

Calcineurin inhibitor

Prograf

151 (85.8)

74 (85.1)

0.87

Cyclosporin

25 (14.2)

13 (14.9)

 

Induction

  

0.24

ATG

30 (17.0)

10 (11.5)

 

Basiliximab

146 (83.0)

77 (88.5)

 

Previous transplant

28 (25.9)

19 (21.8)

0.22

Duration of dialysis (months)

23.6 ± 36.3

29.8 ± 37.3

0.33

Cross-matching results

  

0.91

CDC positive

14 (8.0)

8 (9.2)

 

FCXM positive

162 (92.0)

79 (90.8)

 

T-flow only positive

83 (47.2)

39 (44.8)

 

T- or B- flow positive

79 (44.9)

40 (46.0)

 

PRA class I

42.3 ± 38.0

25.4 ± 34.1

<0.01

PRA class II

35.3 ± 38.4

30.2 ± 39.7

0.36

Maximal DSA (MFI)

7266 ± 4742

7187 ± 4923

0.94

DSA class I (MFI)

5486 ± 4356

3705 ± 4654

0.09

DSA class II (MFI)

5088 ± 5522

5209 ± 5576

0.93

  1. Continuous data are presented as means ± standard deviations, whereas categorical data are presented as numbers (%).
  2. Abbreviations: ATG, anti-thymocyte globulin; CDC, complement-dependent cytotoxicity; FCXM, flow-cytometric crossmatch; PRA, panel reactive antibody; DSA, donor specific antibody; MFI, mean fluorescence intensity.
  3. aCrossmatch-positive (XM+) defined as FCXM-positive or CDC XM-positive; ABOc, ABO compatible; ABOi, ABO incompatible.
Back to article page